Is EVMN or IMDX more profitable?

Evommune has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Company Net Margins Return on Equity Return on Assets Evommune N/A N/A N/A Oncocyte -2,454.64% N/A -96.96%

Does the media prefer EVMN or IMDX?

In the previous week, Evommune and Evommune both had 1 articles in the media. Evommune's average media sentiment score of 0.00 equaled Oncocyte'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evommune 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oncocyte 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SLDB or IMDX?

In the previous week, Solid Biosciences and Solid Biosciences both had 1 articles in the media. Solid Biosciences' average media sentiment score of 1.08 beat Oncocyte's score of 0.00 indicating that Solid Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncocyte 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer RLMD or IMDX?

In the previous week, Relmada Therapeutics had 16 more articles in the media than Oncocyte. MarketBeat recorded 17 mentions for Relmada Therapeutics and 1 mentions for Oncocyte. Relmada Therapeutics' average media sentiment score of 1.05 beat Oncocyte's score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Oncocyte 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, IMDX or CRMD?

CorMedix has higher revenue and earnings than Oncocyte. Oncocyte is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oncocyte $4.05M 42.81 -$50.22M -$1.48 N/A CorMedix $311.71M 2.16 $163.05M $2.13 4.04

Is IMDX or CRMD more profitable?

CorMedix has a net margin of 45.25% compared to Oncocyte's net margin of -2,454.64%. CorMedix's return on equity of 45.57% beat Oncocyte's return on equity. Company Net Margins Return on Equity Return on Assets Oncocyte -2,454.64% N/A -96.96% CorMedix 45.25% 45.57% 24.76%

Does the media prefer IMDX or CRMD?

In the previous week, CorMedix had 1 more articles in the media than Oncocyte. MarketBeat recorded 2 mentions for CorMedix and 1 mentions for Oncocyte. Oncocyte's average media sentiment score of 0.00 equaled CorMedix'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncocyte 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CorMedix 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor DSGN or IMDX?

In the previous week, Design Therapeutics and Design Therapeutics both had 1 articles in the media. Design Therapeutics' average media sentiment score of 0.00 equaled Oncocyte'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oncocyte 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Oncocyte (IMDX) Competitors

$5.37 -0.03 (-0.56%)

Closing price 04:00 PM Eastern

Extended Trading

$5.18 -0.19 (-3.61%)

As of 07:55 PM Eastern

Compare

IMDX vs. EVMN, SLDB, RLMD, CRMD, and DSGN

Should you buy Oncocyte stock or one of its competitors? MarketBeat compares Oncocyte with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oncocyte include Evommune (EVMN), Solid Biosciences (SLDB), Relmada Therapeutics (RLMD), CorMedix (CRMD), and Design Therapeutics (DSGN). These companies are all part of the "pharmaceutical products" industry.

How does Oncocyte compare to Evommune?

Evommune (NYSE:EVMN) and Oncocyte (NASDAQ:IMDX) are both small-cap manufacturing companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Oncocyte has lower revenue, but higher earnings than Evommune. Oncocyte is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	67.27	-$68.87M	-$9.50	N/A
Oncocyte	$4.05M	42.81	-$50.22M	-$1.48	N/A

Evommune currently has a consensus target price of $49.25, suggesting a potential upside of 102.84%. Oncocyte has a consensus target price of $12.00, suggesting a potential upside of 123.46%. Given Oncocyte's higher possible upside, analysts clearly believe Oncocyte is more favorable than Evommune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.00
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Evommune has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	N/A	N/A
Oncocyte	-2,454.64%	N/A	-96.96%

In the previous week, Evommune and Evommune both had 1 articles in the media. Evommune's average media sentiment score of 0.00 equaled Oncocyte'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evommune	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oncocyte	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

55.4% of Oncocyte shares are owned by institutional investors. 2.2% of Oncocyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Evommune beats Oncocyte on 7 of the 12 factors compared between the two stocks.

How does Oncocyte compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Oncocyte (NASDAQ:IMDX) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Solid Biosciences currently has a consensus price target of $17.00, indicating a potential upside of 93.40%. Oncocyte has a consensus price target of $12.00, indicating a potential upside of 123.46%. Given Oncocyte's higher probable upside, analysts clearly believe Oncocyte is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Oncocyte has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
Oncocyte	$4.05M	42.81	-$50.22M	-$1.48	N/A

Solid Biosciences has a beta of 2.43, suggesting that its stock price is 143% more volatile than the broader market. Comparatively, Oncocyte has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market.

Solid Biosciences has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Oncocyte's return on equity of 0.00% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-73.42%	-61.13%
Oncocyte	-2,454.64%	N/A	-96.96%

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 55.4% of Oncocyte shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by company insiders. Comparatively, 2.2% of Oncocyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Solid Biosciences and Solid Biosciences both had 1 articles in the media. Solid Biosciences' average media sentiment score of 1.08 beat Oncocyte's score of 0.00 indicating that Solid Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncocyte	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Solid Biosciences beats Oncocyte on 9 of the 14 factors compared between the two stocks.

How does Oncocyte compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Oncocyte (NASDAQ:IMDX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

Oncocyte has higher revenue and earnings than Relmada Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A
Oncocyte	$4.05M	42.81	-$50.22M	-$1.48	N/A

Relmada Therapeutics has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market. Comparatively, Oncocyte has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market.

Relmada Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 77.25%. Oncocyte has a consensus price target of $12.00, indicating a potential upside of 123.46%. Given Oncocyte's higher possible upside, analysts clearly believe Oncocyte is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 55.4% of Oncocyte shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by insiders. Comparatively, 2.2% of Oncocyte shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Relmada Therapeutics has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Oncocyte's return on equity of 0.00% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-71.22%	-64.46%
Oncocyte	-2,454.64%	N/A	-96.96%

In the previous week, Relmada Therapeutics had 16 more articles in the media than Oncocyte. MarketBeat recorded 17 mentions for Relmada Therapeutics and 1 mentions for Oncocyte. Relmada Therapeutics' average media sentiment score of 1.05 beat Oncocyte's score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncocyte	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Relmada Therapeutics beats Oncocyte on 9 of the 15 factors compared between the two stocks.

How does Oncocyte compare to CorMedix?

Oncocyte (NASDAQ:IMDX) and CorMedix (NASDAQ:CRMD) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Oncocyte has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market. Comparatively, CorMedix has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

CorMedix has a net margin of 45.25% compared to Oncocyte's net margin of -2,454.64%. CorMedix's return on equity of 45.57% beat Oncocyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,454.64%	N/A	-96.96%
CorMedix	45.25%	45.57%	24.76%

In the previous week, CorMedix had 1 more articles in the media than Oncocyte. MarketBeat recorded 2 mentions for CorMedix and 1 mentions for Oncocyte. Oncocyte's average media sentiment score of 0.00 equaled CorMedix'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncocyte	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CorMedix	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oncocyte currently has a consensus target price of $12.00, suggesting a potential upside of 123.46%. CorMedix has a consensus target price of $15.00, suggesting a potential upside of 74.42%. Given Oncocyte's higher possible upside, equities research analysts clearly believe Oncocyte is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

CorMedix has higher revenue and earnings than Oncocyte. Oncocyte is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncocyte	$4.05M	42.81	-$50.22M	-$1.48	N/A
CorMedix	$311.71M	2.16	$163.05M	$2.13	4.04

55.4% of Oncocyte shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 2.2% of Oncocyte shares are owned by company insiders. Comparatively, 3.5% of CorMedix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

CorMedix beats Oncocyte on 10 of the 14 factors compared between the two stocks.

How does Oncocyte compare to Design Therapeutics?

Design Therapeutics (NASDAQ:DSGN) and Oncocyte (NASDAQ:IMDX) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 55.4% of Oncocyte shares are held by institutional investors. 17.1% of Design Therapeutics shares are held by insiders. Comparatively, 2.2% of Oncocyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Oncocyte has higher revenue and earnings than Design Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
Oncocyte	$4.05M	42.81	-$50.22M	-$1.48	N/A

Design Therapeutics currently has a consensus target price of $16.50, indicating a potential upside of 20.09%. Oncocyte has a consensus target price of $12.00, indicating a potential upside of 123.46%. Given Oncocyte's higher probable upside, analysts plainly believe Oncocyte is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Design Therapeutics has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market. Comparatively, Oncocyte has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market.

In the previous week, Design Therapeutics and Design Therapeutics both had 1 articles in the media. Design Therapeutics' average media sentiment score of 0.00 equaled Oncocyte'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oncocyte	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Design Therapeutics has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Oncocyte's return on equity of 0.00% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-33.07%	-31.29%
Oncocyte	-2,454.64%	N/A	-96.96%

Summary

Design Therapeutics beats Oncocyte on 8 of the 13 factors compared between the two stocks.

Get Oncocyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMDX vs. The Competition

Export

Metric	Oncocyte	In Vitro, In Vivo Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$174.37M	$616.18M	$4.36B	$12.11B
Dividend Yield	N/A	N/A	10.94%	5.81%
P/E Ratio	N/A	N/A	22.07	24.00
Price / Sales	42.81	152.04	206.72	90.40
Price / Cash	N/A	373.88	41.09	37.84
Price / Book	-4.88	37.76	18.63	6.53
Net Income	-$50.22M	-$18.48M	$115.37M	$336.99M
7 Day Performance	0.94%	-0.32%	-0.49%	-0.22%
1 Month Performance	-11.82%	-12.03%	-1.84%	0.77%
1 Year Performance	N/A	-46.90%	12.71%	31.57%

Oncocyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMDX Oncocyte	1.9258 of 5 stars	$5.37 -0.6%	$12.00 +123.5%	N/A	$174.37M	$4.05M	N/A	120	News Coverage
EVMN Evommune	2.1048 of 5 stars	$20.66 +4.2%	$49.25 +138.4%	N/A	$714.24M	$13M	N/A	45
SLDB Solid Biosciences	2.8412 of 5 stars	$7.36 +3.1%	$17.00 +131.0%	+73.3%	$702.93M	N/A	N/A	100	Positive News
RLMD Relmada Therapeutics	2.3017 of 5 stars	$6.37 -4.2%	$12.00 +88.4%	+915.5%	$697.52M	N/A	N/A	10	Positive News Analyst Revision Gap Down High Trading Volume
CRMD CorMedix	2.9774 of 5 stars	$8.59 -1.7%	$15.00 +74.6%	-35.2%	$685.67M	$311.71M	4.03	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMDX) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oncocyte (IMDX) Competitors

IMDX vs. EVMN, SLDB, RLMD, CRMD, and DSGN

How does Oncocyte compare to Evommune?

Summary

How does Oncocyte compare to Solid Biosciences?

Summary

How does Oncocyte compare to Relmada Therapeutics?

Summary

How does Oncocyte compare to CorMedix?

Summary

How does Oncocyte compare to Design Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMDX vs. The Competition

Oncocyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oncocyte (IMDX) Competitors

IMDX vs. EVMN, SLDB, RLMD, CRMD, and DSGN

How does Oncocyte compare to Evommune?

Which has stronger earnings & valuation, EVMN or IMDX?

Do analysts prefer EVMN or IMDX?

Is EVMN or IMDX more profitable?

Does the media prefer EVMN or IMDX?

Do institutionals & insiders hold more shares of EVMN or IMDX?

Summary

How does Oncocyte compare to Solid Biosciences?

Do analysts recommend SLDB or IMDX?

Which has stronger earnings and valuation, SLDB or IMDX?

Which has more volatility and risk, SLDB or IMDX?

Is SLDB or IMDX more profitable?

Do institutionals and insiders have more ownership in SLDB or IMDX?

Does the media refer more to SLDB or IMDX?

Summary

How does Oncocyte compare to Relmada Therapeutics?

Which has stronger earnings and valuation, RLMD or IMDX?

Which has more volatility & risk, RLMD or IMDX?

Do analysts prefer RLMD or IMDX?

Do insiders & institutionals have more ownership in RLMD or IMDX?

Is RLMD or IMDX more profitable?

Does the media prefer RLMD or IMDX?

Summary

How does Oncocyte compare to CorMedix?

Which has more risk and volatility, IMDX or CRMD?

Is IMDX or CRMD more profitable?

Does the media prefer IMDX or CRMD?

Do analysts recommend IMDX or CRMD?

Which has higher earnings & valuation, IMDX or CRMD?

Do insiders & institutionals hold more shares of IMDX or CRMD?

Summary

How does Oncocyte compare to Design Therapeutics?

Do insiders & institutionals have more ownership in DSGN or IMDX?

Which has better valuation & earnings, DSGN or IMDX?

Do analysts recommend DSGN or IMDX?

Which has more risk and volatility, DSGN or IMDX?

Does the media favor DSGN or IMDX?

Is DSGN or IMDX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMDX vs. The Competition

Oncocyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools